Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A

Trial Profile

Safety and Efficacy of N8 in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Turoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Adverse reactions
  • Acronyms guardian-2
  • Sponsors Novo Nordisk; Novo Nordisk Pharma
  • Most Recent Events

    • 19 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
    • 03 Jul 2017 According to Novo Nordisk media release, data from this trial will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) congress 2017.
    • 06 Dec 2016 Interim results from guardian™2 trial (n=199) and on-demand subtrial (n=19) of turoctocog alfa, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top